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test score indicating likely benefit from chemotherapy, doctor’s estimate of risk 
of cancer returning (based on clinical algorithms), likelihood of permanent side 
effects, trust in cancer treatment doctor, and likelihood of temporary side 
effects. In a scenario of intermediate risk of cancer returning based on clinical 
algorithms alone (no GEP score), 12% of respondents chose chemotherapy 
compared to 89% of respondents with a GEP score of 44 (high likelihood of 
benefit from chemotherapy). CONCLUSIONS: GEP testing is highly valued and 
strongly influences chemotherapy treatment decisions in all three groups. These 
findings provide preliminary evidence supporting the clinical utility of GEP in 
BrCa treatment decisions.  
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OBJECTIVES: Prostate cancer is the most prevalent form of cancer in men and 
the leading cause of cancer death. In the majority of cases, prostate cancer will 
become castration-resistant; a progressive state whereby most patients develop 
BM with an associated impact on quality of life and life expectancy. We 
evaluated the impact of BM on performance status (Karnofsky score) and pain 
indicators (EQ-5D and FACT-P) in patients with CRPC. METHODS: Data were 
extracted from the Adelphi Real World Prostate Cancer Disease-Specific 
Programme©(DSP), a cross-sectional survey of 348 urologists/oncologists and 
their prostate cancer patients, conducted December 2009–May 2010 in France, 
Germany, Italy, Spain and the UK. Each physician completed comprehensive 
record forms on 10 patients receiving treatment for prostate cancer. Patients 
were also invited to complete a questionnaire, which included EQ-5D and FACT-
P tools. RESULTS: Of the 3477 prostate cancer patients included, 1180 (34%) were 
defined as having CRPC with a median time since diagnosis of 35.8 months: 146 
(12%) patients were categorized as being high risk for developing BM (‘high risk’: 
Gleason score ≥8, or, most recent PSA≥8ng/mL, or, PSADT≤6 months, or, received 
local therapy + systemic medication); 680 (58%) patients had BM. Karnofsky 
scores of 85.1 and 75.7 were reported for high risk patients and those with BM, 
respectively (p<0.0001). Symptoms were reported in 60 (41%) and 487 (72%) high 
risk and BM patients, respectively (p<0.0001) and no pain/discomfort (EQ-5D) was 
reported by 19 (51%) vs 38 (23%) patients (p=0.0009), respectively. Eleven (41%) 
high risk patients and 21 (14%) patients with BM stated no impact of pain on 
daily activities (FACT-P) (p=0.0026). CONCLUSIONS: Developing BM impacts 
patient performance status and pain burden. There is a need for treatments to 
prevent or delay the onset of BM thereby delaying their associated humanistic 
burden.  
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OBJECTIVES: Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a 
cancer in which anemia is common. The Functional Assessment of Cancer 
Therapy (FACT) –Anemia instrument measures general quality of life (QOL) and 
anemia-related concerns of people with cancer. We assessed the relationship 
between anemia response to therapy with pomalidomide and domains of the 
FACT-An instrument. METHODS: Data were from a phase-2 randomized double-
blind Bayesian “pick-the-winner” trial of pomalidomide and prednisone in 
subjects with MPN-associated myelofibrosis and anemia (including RBC-
transfusion-dependence). Details of the study, including definitions of anemia 
response, RBC-transfusion-dependence and –independence are reported. Change 
in QOL from randomization to the last cycle of therapy was evaluated using the 
FACT-An physical well-being (PWB), functional well-being (FWB), trial outcome 
index (TOI) and anemia (An) domains. Minimally clinically important differences 
(MID) were used to determine the smallest difference in scores which subjects 
perceived as beneficial in the FACT-An domains of interest. Subjects were 
classified as meeting MID for responsiveness if their change score from baseline 
was greater than one standard error of measurement (SEM) indicating 
improvement. RESULTS: Eighty-five subjects were studied. All FACT-An domains 
showed strong reliability as measured by Cronbach alpha (PWB α=0.77, FWB 
α=0.87, An α=0.92, TOI α=0.95). Thirty-one subjects were classified as anemia 
responders by clinical and laboratory criteria. Anemia responders showed 
greater improvement in PWB, FWB and TOI scores than non-responders across 
all FACT-An domains. Improvement began at the second 28 day cycle of therapy 
and was sustained. CONCLUSIONS: We show anemia response correlates with 
improved QOL measured by the FACT-An instrument in persons with MPN-
associated myelofibrosis receiving pomalidomide.  
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OBJECTIVES: To evaluate the impact that patient-reported outcomes (PRO) and 
health economic (HE) benefit claims made in product labels and in published 
literature have on market value of oncologic pharmaceuticals in the US. 
METHODS: A target list of 13 advanced/metastatic cancers and 32 drugs with 
labeled indications for them were combined into 37 unique “drug-indication 
pairs.” Drugs were antineoplastic agents with FDA approval ≤ 2009. PRO claims in 
US and EMA labels were identified through a commercial research database. PRO 
and HE claims made in published literature were identified through review of 
abstracts published 2000-2010. Economic data (i.e., market size and market share 
in 2010) for drug-indication pairs were extracted from MarketScan® claims 
databases. Data were compiled into an analytic file and one primary and four 
secondary regression models were specified, adjusting for relative drug safety 
and efficacy. The dependant variable in each model represented dollar-value 
market share in 2010 of each drug in its cancer indication. RESULTS: Results 
indicate that PRO claims in US product labels are associated with positive 
increases in market value of oncologic pharmaceuticals. Presence of a label PRO 
claim was associated with 66% increase in market share—about the same 
economic impact conferred by superior drug efficacy. Results were not 
statistically significant in the model for US labels alone (p<0.18), but were 
significant when combining US and EMA labels (p<0.03). No significant 
association was found between PRO and HE claims made in published literature 
and market value of oncologic pharmaceuticals. CONCLUSIONS: Our analysis 
fills gaps in understanding the economic value of PRO and HE benefit claims for 
oncologic pharmaceuticals and sets precedence for undertaking similar studies 
in oncology and other disease areas. Results reinforce that industry should 
carefully evaluate potential positive returns for investing in inclusion of PRO and 
HE endpoints in clinical trials.  
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OBJECTIVES: Malignant gliomas are highly proliferative, invasive tumors that are 
resistant to conventional treatment and are typically accompanied by 
progressive physical and mental debilitation. We evaluated neurocognitive 
functioning (NCF) and quality of life (QOL) as part of a prospective Phase Ib dose-
escalation study of topotecan by CED in patients with recurrent gliomas. 
METHODS: Secondary data analysis was conducted on the 16 patients enrolled 
on the Phase Ib study. Independent-sample t-tests were used to explore 
differences. Patients received serial assessments at baseline, 1-, 2-, 3-, and 4-
months post-treatment. NCF and QOL were assessed using the HeadMinder 
Cognitive Stability Index and the SF-36, respectively. RESULTS: Patients were 
predominantly male (68.7%) with a median age of 50 years (Range=22-71 years). 
Tumor volume and total infused dose of topotecan were not associated with any 
of the outcome variables. NCF was better for early responders (ERs) than patients 
with progressive disease (PD) or pseudoprogression (PP). Processing speed for ERs 
(n=4) averaged over the follow-up period was significantly higher (z=1.95 SD) 
than patients with PD (n=5; z=-0.61 SD) (p=0.006). Similarly, change in response 
time was better for ERs compared to those with PD (z=4.40 SD; z=-0.52, 
respectively; p=0.04). At baseline, SF-36 results for physical and mental QOL were 
within normal limits. Relative to baseline, average change in SF-36 scores post-
treatment suggest that overall mental QOL was significantly higher for ERs (MCS 
change score=5.04) than patients with PD (MCS change score=-6.48) (p=0.02), 
reflecting better emotional well-being. Average change in physical QOL was not 
significantly different between ERs, PD or PP. CONCLUSIONS: These results 
provide the beginning framework to better understand NCF/QOL outcomes in 
patients with recurrent malignant gliomas treated with topotecan by CED. 
Continued monitoring of these outcomes will be important in the phase II trial to 
assess treatment efficacy and impact on NCF and QOL.  
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OBJECTIVES: To compare dynamic changes of the health-related quality of life 
(HRQL) in patients with invasive cervical cancer and carcinoma in situ for 
estimation of potential gain in quality of life from early detection. METHODS: All 
patients diagnosed with cervical cancer who visited the cancer clinic at the 
National Cheng Kung University Hospital from March 2012 to September 2012 
were invited to participate in the study. They were classified into 4 groups 
according to treatment modalities: Carcinoma in situ post conization, invasive 
cancer treated with operation only, those treated with operation plus 
chemotherapy or radiotherapy, and those treated with chemotherapy or 
radiotherapy only. The WHOQOL-BREF (World Health Organization Quality of 
Life – brief version) questionnaire was used to measure the HRQL. The dynamic 
changes of HRQL scores were calculated with the kernel smoothing method.  
A mixed-effect model was constructed to analyze repeated measurements and 
determine risk factors for impairment of HRQL and different treatment 
modalities. RESULTS: A total of 507 measurements were collected from 421 
patients. In comparison with carcinoma-in-situ patients post conization, 
patients with invasive cervical cancer who received operation plus 
chemotherapy or radiotherapy showed consistently lower scores in facets  
of physical and psychological domains and sexual activities after adjustment for 
age, education, marital status, co-morbidities and duration after diagnosis.  
The differences in scores seemed to be reduced temporarily 4-8 years after 
diagnosis. CONCLUSIONS: Early detection of cervical cancer may avoid 
impairment of quality of life in physical, psychological domains, and sexual 
activities.  
